<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5770">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096550</url>
  </required_header>
  <id_info>
    <org_study_id>1RC1DA028407-01</org_study_id>
    <secondary_id>1RC1DA028407-01</secondary_id>
    <nct_id>NCT01096550</nct_id>
  </id_info>
  <brief_title>Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans</brief_title>
  <official_title>Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Friends Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Friends Research Institute, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of different levels of counseling
      (intensive outpatient versus standard outpatient) on treatment outcomes for African American
      adult patients receiving buprenorphine in 2 formerly &quot;drug-free&quot; programs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This two-group randomized clinical trial will test the effectiveness of intensive outpatient
      (IOP) v. standard outpatient (OP) treatment in 272 heroin-dependent African American adults
      receiving buprenorphine in 2 formerly &quot;drug-free&quot; programs. Participants will be randomly
      assigned to one of the two treatment intensity conditions at intake and assessed at
      baseline, 3-, and 6-months post-baseline to determine treatment retention, frequency and
      severity of heroin and cocaine use, self-reported HIV-risk, quality of life, and to
      determine DSM-IV criteria for Full or Partial Remission of Opioid Dependence. Furthermore,
      patient factors potentially critical for treatment success (e.g., attitudes towards
      buprenorphine and average buprenorphine dose while in treatment) will be examined to
      determine their importance in influencing treatment outcomes. Moreover, both patient and
      staff attitudes and average buprenorphine dose will be evaluated to determine their
      respective relationships to treatment experiences and treatment retention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Meeting Diagnosis of Opioid Dependence on Composite International Diagnostic Interview-2 (CIDI-2)</measure>
    <time_frame>6 months post-baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">319</enrollment>
  <condition>Drug Dependence</condition>
  <arm_group>
    <arm_group_label>Intensive Outpatient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine patients receiving 9 or more hours of outpatient counseling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Outpatient</intervention_name>
    <description>Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.</description>
    <arm_group_label>Outpatient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive Outpatient</intervention_name>
    <description>Buprenorphine patients receiving 9 or more hours of outpatient counseling.</description>
    <arm_group_label>Intensive Outpatient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  heroin-dependent adults

          -  new admissions to buprenorphine outpatient treatment

        Exclusion Criteria:

          -  pregnancy

          -  acute medical or psychiatric illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon G Mitchell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 25, 2015</lastchanged_date>
  <firstreceived_date>March 30, 2010</firstreceived_date>
  <firstreceived_results_date>August 13, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <keyword>outpatient treatment</keyword>
  <keyword>intensive outpatient treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>New patients entering buprenorphine treatment at one of the two participating outpatient “drug-free” treatment programs were block randomized to either intensive outpatient treatment (IOP) or standard outpatient treatment (OP). The study initially included a third clinic site, which was dropped due to insufficient enrollment at that site.</recruitment_details>
      <pre_assignment_details>345 patients were randomized. Of those, the following participants were excluded from the study shortly after random assignment: 21 were from the discontinued site, 2 were dropped because of non-standard clinic treatment track, 1 voluntarily withdrew, 2 were erroneously re-enrolled. We also excluded 19 non-African Americans, per study protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intensive Outpatient</title>
          <description>Buprenorphine patients receiving 9 or more hours of outpatient counseling.
Intensive Outpatient : Buprenorphine patients receiving 9 or more hours of outpatient counseling.</description>
        </group>
        <group group_id="P2">
          <title>Outpatient</title>
          <description>Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
Outpatient : Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>discontinued site</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-regular treatment track at clinic</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>clinic readmission</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-African American participant</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>21 were from the discontinued site, 2 dropped because participant was non-regular treatment track, 1 voluntarily withdrew from the study, 1 was erroneously re-enrolled after being re-admitted to the same clinic, and 1 was erroneously re-enrolled, and 19 were not African American.</population>
      <group_list>
        <group group_id="B1">
          <title>Intensive Outpatient</title>
          <description>Buprenorphine patients receiving 9 or more hours of outpatient counseling.
Intensive Outpatient : Buprenorphine patients receiving 9 or more hours of outpatient counseling.</description>
        </group>
        <group group_id="B2">
          <title>Outpatient</title>
          <description>Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
Outpatient : Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="170"/>
                <measurement group_id="B2" value="175"/>
                <measurement group_id="B3" value="345"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="168"/>
                <measurement group_id="B2" value="174"/>
                <measurement group_id="B3" value="342"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44.15" spread="8.15"/>
                <measurement group_id="B2" value="46.27" spread="6.75"/>
                <measurement group_id="B3" value="45.23" spread="7.53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="67"/>
                <measurement group_id="B3" value="129"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="108"/>
                <measurement group_id="B2" value="108"/>
                <measurement group_id="B3" value="216"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="170"/>
                <measurement group_id="B2" value="175"/>
                <measurement group_id="B3" value="345"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Meeting Diagnosis of Opioid Dependence on Composite International Diagnostic Interview-2 (CIDI-2)</title>
        <time_frame>6 months post-baseline</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intensive Outpatient</title>
            <description>Buprenorphine patients receiving 9 or more hours of outpatient counseling.
Intensive Outpatient : Buprenorphine patients receiving 9 or more hours of outpatient counseling.</description>
          </group>
          <group group_id="O2">
            <title>Outpatient</title>
            <description>Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
Outpatient : Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                  <measurement group_id="O2" value="155"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Meeting Diagnosis of Opioid Dependence on Composite International Diagnostic Interview-2 (CIDI-2)</title>
            <units>percentage of opioid dependent subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intensive Outpatient</title>
          <description>Buprenorphine patients receiving 9 or more hours of outpatient counseling.
Intensive Outpatient : Buprenorphine patients receiving 9 or more hours of outpatient counseling.</description>
        </group>
        <group group_id="E2">
          <title>Outpatient</title>
          <description>Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
Outpatient : Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>OP condition participants received more counseling services at the clinics as part of their regular care than was initially expected and IOP condition participants received slightly less that 9 hours of counseling, on average.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Shannon Gwin Mitchell</name_or_title>
      <organization>Friends Research Institute</organization>
      <phone>410-837-3977 ext 238</phone>
      <email>smitchell@friendsresearch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
